Monte Rosa doses first patients with molecular glue degrader designed to treat multiple conditions driven by the NLRP3 inflammasome.
Boston-based biotech Monte Rosa Therapeutics has begun dosing participants in a Phase 1 clinical trial evaluating MRT-8102, a molecular glue degrader (MGD) designed to target NEK7, a protein implicated in inflammatory conditions driven by the NLRP3 inflammasome. The investigational therapy is being developed as an oral treatment intended to address a range of diseases associated with chronic inflammation.
MGDs are a class of small molecules that work by promoting the degradation of specific target proteins within cells, linking them to the cell’s natural protein-disposal system. Unlike conventional inhibitors, MGDs eliminate their target entirely rather than simply blocking its activity. MRT-8102 is designed to degrade NEK7, a protein that plays a pivotal role in enabling NLRP3 inflammasome activation along with downstream cytokines IL-1β and IL-6. Dysregulation of this pathway is associated with a broad range of conditions, including cardiovascular disease, osteoarthritis and neurological disorders such as Parkinson’s disease and Alzheimer’s disease.
NEK7 functions as a scaffold protein that physically interacts with NLRP3, facilitating the assembly and activation of the inflammasome. Without NEK7, the NLRP3 inflammasome cannot efficiently form or activate, preventing downstream signaling and release of proinflammatory cytokines. According to Monta Rosa, its preclinical studies demonstrated that MRT-8102 selectively and durably degraded NEK7 and leads to near-complete suppression of IL-1β production following stimulation of immune cells in a non-human primate model. The company also claims its drug has demonstrated a significant safety margin, exceeding 200-fold over the projected human therapeutic dose in toxicology studies.
In addition to evaluating safety, tolerability, pharmacokinetics, the Phase 1 trial will study pharmacodynamic markers such as NEK7 protein levels and responses to inflammasome activation. An additional cohort will enroll individuals with elevated cardiovascular risk due to obesity and increased C-reactive protein (CRP) levels. This group will enable the evaluation of early biological effects in a population with systemic inflammation, assessing changes in CRP and other inflammatory markers that may signal early therapeutic activity.
“MRT-8102 is the only clinical-stage MGD that selectively targets NEK7, a protein central to NLRP3 inflammasome activation and the downstream dysregulation of IL-1β and IL-6 that underlie multiple inflammatory diseases,” said Monte Rosa CEO Dr Markus Warmuth. “We believe MRT-8102 could offer a differentiated approach to treating these diseases based on the exciting potency, selectivity, and durable pharmacodynamics seen in our preclinical studies.”
Initial results from the ongoing trial are expected in the first half of 2026.
